India's pharmaceutical sector is transitioning from a generics-focused model toward investment in innovative drug development, biotech startups, and venture-capital funding [1].

This shift represents a strategic pivot for one of the world's largest drug producers. Moving beyond the replication of existing medicines allows India to capture higher-value patents and reduce reliance on foreign intellectual property.

Priyanka Aggarwal, a senior partner at Boston Consulting Group, said during a June interview that further work is likely needed to strengthen the R&D supply chain [1]. While the ecosystem is growing, the scale of investment remains a significant hurdle compared to global leaders.

Aggarwal noted a stark contrast in financial commitments to research. She said the U.S. spends roughly $70 billion to $75 billion on pharmaceutical R&D each year, while India’s spending sits at $2 billion to $3 billion [1].

Despite the spending gap, the industry is seeing a surge in biotech startups and increased inflows of venture capital [2]. These drivers are creating a push for home-grown innovation that departs from the traditional manufacturing-heavy approach [2].

Analysts suggest that India's deep roots in life sciences have traditionally been based in manufacturing and replication [2]. However, recent successes in novel drug development indicate that a domestic innovation industry is within reach [2].

External pressures are also influencing the landscape. The U.S. administration announced tariffs on branded pharmaceuticals in April 2026, adding a geopolitical layer to the need for domestic resilience [3]. Strengthening the R&D supply chain is now viewed as essential to sustain this transition and ensure the industry is not only tariff-proof but also resilient against global supply shocks [3].

“Further work is likely needed to strengthen the R&D supply chain.”

India is attempting to move up the value chain from a 'pharmacy to the world' based on low-cost generics to a global hub for drug discovery. While the growth of biotech startups and venture capital provides the momentum, the massive disparity in R&D spending compared to the U.S. suggests that India must significantly scale its infrastructure and funding to become a primary innovator rather than a secondary manufacturer.